Remodeling components of the tumor microenvironment to enhance cancer therapy

Frontiers in Oncology

Volumn 5, Issue OCT, 2015, Pages

  Gkretsi, Vasiliki ^a   Stylianou, Andreas ^a   Papageorgis, Panagiotis ^a,b   Polydorou, Christiana ^a   Stylianopoulos, Triantafyllos ^a  

^a UNIVERSITY OF CYPRUS   (Cyprus)

^b EUROPEAN UNIVERSITY CYPRUS   (Cyprus)

Author keywords

In vitro models; Stress alleviation; Tumor vessel permeability; Vascular normalization; Vessel compression

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

APOPTOSIS; ATOMIC FORCE MICROSCOPY; BLOOD VESSEL PERMEABILITY; BREAST TUMOR; CANCER THERAPY; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CHROMOSOME ABERRATION; COLON CANCER; EXTRACELLULAR MATRIX; GLIOBLASTOMA; HUMAN; LIVER CELL CARCINOMA; MECHANICAL STRESS; NONHUMAN; PANCREAS CANCER; REVIEW; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR VASCULARIZATION;

EID: 84947049994     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00214     Document Type: Review

References (165)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell (2000) 100:57-70. doi:10.1016/S0092-8674(00)81683-9
2. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 21:309-22. doi:10.1016/j.ccr.2012.02.022
3. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 9:162-74. doi:10.1038/nri2506
4. Chow A, Brown BD, Merad M. Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol (2011) 11:788-98. doi:10.1038/nri3087
5. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol (2011) 11:519-31. doi:10.1038/nri3024
6. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng (2014) 16:321-46. doi:10.1146/annurev-bioeng-071813-105259
7. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res (1986) 31:288-305. doi:10.1016/0026-2862(86)90018-X
8. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res (1986) 46:6387-92.
9. Jain RK. Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 6:559-93. doi:10.1007/BF00047468
10. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res (2010) 2:14. doi:10.1186/2040-2384-2-14
11. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 95:4607-12. doi:10.1073/pnas.95.8.4607
12. Hashizume H, Baluk P, Morikawa S, Mclean JW, Thurston G, Roberge S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 156:1363-80. doi:10.1016/S0002-9440(10)65006-7
13. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 73:2943-8. doi:10.1158/0008-5472.CAN-12-4354
14. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell (2014) 26:605-22. doi:10.1016/j.ccell.2014.10.006
15. Calcinotto A, Filipazzi P, Grioni M, Iero M, De Milito A, Ricupito A, et al. Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes. Cancer Res (2012) 72:2746-56. doi:10.1158/0008-5472.CAN-11-1272
16. Palazón A, Aragonés J, Morales-Kastresana A, Ortiz De Landázuri M, Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin Cancer Res (2012) 18:1207-13. doi:10.1158/1078-0432.CCR-11-1591
17. Motz G, Coukos G. Deciphering and reversing tumor immune suppression. Immunity (2013) 39:61-73. doi:10.1016/j.immuni.2013.07.005
18. Casazza A, Di Conza G, Wenes M, Finisguerra V, Deschoemaeker S, Mazzone M. Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment. Oncogene (2014) 33:1743-54. doi:10.1038/onc.2013.121
19. Semenza GL. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol (2014) 9:47-71. doi:10.1146/annurev-pathol-012513-104720
20. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer (2011) 11:393-410. doi:10.1038/nrc3064
21. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res (1991) 51:6691-4.
22. Boucher Y, Jain RK. Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res (1992) 52:5110-4.
23. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 7:383-8. doi:10.1038/nnano.2012.45
24. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv (2013) 4:421-3. doi:10.4155/tde.13.8
25. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2:281-98. doi:10.1146/annurev-chembioeng-061010-114300
26. Jain RK, Tong RT, Munn LL. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res (2007) 67:2729-35. doi:10.1158/0008-5472.CAN-06-4102
27. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 59:3776-82.
28. Padera TP, Stoll BR, Tooredman JB, Capen D, Di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature (2004) 427:695. doi:10.1038/427695a
29. Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR, Jain RK. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res (2013) 73:3833-41. doi:10.1158/0008-5472.CAN-12-4521
30. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110:673-87. doi:10.1016/S0092-8674(02)00971-6
31. Briquez PS, Hubbell JA, Martino MM. Extracellular matrix-inspired growth factor delivery systems for skin wound healing. Adv Wound Care (New Rochelle) (2015) 4:479-89. doi:10.1089/wound.2014.0603
32. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315:1650-9.
33. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol (2008) 9:628-38. doi:10.1038/nrm2455
34. Papageorgis P, Stylianopoulos T. Role of TGFbeta in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 46:933-43. doi:10.3892/ijo.2015.2816
35. Koperek O, Asari R, Niederle B, Kaserer K. Desmoplastic stromal reaction in papillary thyroid microcarcinoma. Histopathology (2011) 58:919-24. doi:10.1111/j.1365-2559.2011.03791.x
36. Cardone A, Tolino A, Zarcone R, Borruto Caracciolo G, Tartaglia E. Prognostic value of desmoplastic reaction and lymphocytic infiltration in the management of breast cancer. Panminerva Med (1997) 39:174-7.
37. Ueno H, Shinto E, Hashiguchi Y, Shimazaki H, Kajiwara Y, Sueyama T, et al. In rectal cancer, the type of desmoplastic response after preoperative chemoradiotherapy is associated with prognosis. Virchows Arch (2015) 466:655-63. doi:10.1007/s00428-015-1756-1
38. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer (2004) 4:839-49. doi:10.1038/nrc1477
39. Kharaishvili G, Simkova D, Bouchalova K, Gachechiladze M, Narsia N, Bouchal J. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int (2014) 14:41. doi:10.1186/1475-2867-14-41
40. Torimura T, Ueno T, Inuzuka S, Kin M, Ohira H, Kimura Y, et al. The extracellular matrix in hepatocellular carcinoma shows different localization patterns depending on the differentiation and the histological pattern of tumors: immunohistochemical analysis. J Hepatol (1994) 21:37-46. doi:10.1016/S0168-8278(94)80134-7
41. Schedin P, Keely PJ. Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol (2011) 3:a003228. doi:10.1101/cshperspect.a003228
42. Iozzo RV, Sampson PM, Schmitt GK. Neoplastic modulation of extracellular matrix: stimulation of chondroitin sulfate proteoglycan and hyaluronic acid synthesis in co-cultures of human colon carcinoma and smooth muscle cells. J Cell Biochem (1989) 39:355-78. doi:10.1002/jcb.240390403
43. Bouziges F, Simo P, Simon-Assmann P, Haffen K, Kedinger M. Altered deposition of basement-membrane molecules in co-cultures of colonic cancer cells and fibroblasts. Int J Cancer (1991) 48:101-8. doi:10.1002/ijc.2910480119
44. Rutka JT, Myatt CA, Giblin JR, Davis RL, Rosenblum ML. Distribution of extracellular matrix proteins in primary human brain tumours: an immunohistochemical analysis. Can J Neurol Sci (1987) 14:25-30.
45. Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, et al. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion. PLoS One (2010) 5:e9808. doi:10.1371/journal.pone.0009808
46. Le Bail B, Faouzi S, Boussarie L, Balabaud C, Bioulac-Sage P, Rosenbaum J. Extracellular matrix composition and integrin expression in early hepatocarcinogenesis in human cirrhotic liver. J Pathol (1997) 181:330-7. doi:10.1002/(SICI)1096-9896(199703)181:3<330::AID-PATH765>3.0.CO;2-7
47. Fisseler-Eckhoff A, Prebeg M, Voss B, Muller KM. Extracellular matrix in preneoplastic lesions and early cancer of the lung. Pathol Res Pract (1990) 186:95-101. doi:10.1016/S0344-0338(11)81016-2
48. Whatcott CJ, Diep CH, Jiang P, Watanabe A, Lobello J, Sima C, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res (2015) 21:3561-8. doi:10.1158/1078-0432.CCR-14-1051
49. Linder S, Castanos-Velez E, Von Rosen A, Biberfeld P. Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. Hepatogastroenterology (2001) 48:1321-7.
50. Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, et al. Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 109:15101-8. doi:10.1073/pnas.1213353109
51. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 3:177-82. doi:10.1038/nm0297-177
52. Kaufman LJ, Brangwynne CP, Kasza KE, Filippidi E, Gordon VD, Deisboeck TS, et al. Glioma expansion in collagen I matrices: analyzing collagen concentration-dependent growth and motility patterns. Biophys J (2005) 89:635-50. doi:10.1529/biophysj.105.061994
53. Cheng G, Tse J, Jain RK, Munn LL. Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS One (2009) 4:e4632. doi:10.1371/journal.pone.0004632
54. Demou ZN. Gene expression profiles in 3D tumor analogs indicate compressive strain differentially enhances metastatic potential. Ann Biomed Eng (2010) 38:3509-20. doi:10.1007/s10439-010-0097-0
55. Tse JM, Cheng G, Tyrrell JA, Wilcox-Adelman SA, Boucher Y, Jain RK, et al. Mechanical compression drives cancer cells toward invasive phenotype. Proc Natl Acad Sci U S A (2012) 109:911-6. doi:10.1073/pnas.1118910109
56. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7:653-64. doi:10.1038/nrclinonc.2010.139
57. Yuan F, Salehi HA, Boucher Y, Vasthare US, Tuma RF, Jain RK. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res (1994) 54:4564-8.
58. Popovic Z, Liu W, Chauhan VP, Lee J, Wong C, Greytak AB, et al. A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 49:8649-52. doi:10.1002/anie.201003142
59. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med (2004) 10:789-99. doi:10.1038/nm1087
60. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem (2013) 59:85-93. doi:10.1373/clinchem.2012.185363
61. Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev (2011) 91:1071-121. doi:10.1152/physrev.00038.2010
62. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res (2004) 64:3731-6. doi:10.1158/0008-5472.CAN-04-0074
63. Zhang L, Hannay JA, Liu J, Das P, Zhan M, Nguyen T, et al. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res (2006) 66:8770-8. doi:10.1158/0008-5472.CAN-06-1217
64. Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res (2011) 71:998-1008. doi:10.1158/0008-5472.CAN-09-3269
65. Cho HJ, Kim IK, Park SM, Baek KE, Nam IK, Park SH, et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer (2014) 135:1553-63. doi:10.1002/ijc.28801
66. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell (2008) 30:393-402. doi:10.1016/j.molcel.2008.04.009
67. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu N, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 94:715-25. doi:10.1016/S0092-8674(00)81731-6
68. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 121:335-48. doi:10.1016/j.cell.2005.02.034
69. Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell (2009) 15:21-34. doi:10.1016/j.ccr.2008.12.004
70. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 5:e19. doi:10.1371/journal.pmed.0050019
71. Jain RK, Booth MF. What brings pericytes to tumor vessels? J Clin Invest (2003) 112:1134-6. doi:10.1172/JCI200320087
72. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci (2010) 123:4195-200. doi:10.1242/jcs.023820
73. Schaefer L, Schaefer RM. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res (2010) 339:237-46. doi:10.1007/s00441-009-0821-y
74. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 196:395-406. doi:10.1083/jcb.201102147
75. Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol (2010) 341:126-40. doi:10.1016/j.ydbio.2009.10.026
76. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol (1999) 181:153-9. doi:10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K
77. Myllyharju J, Kivirikko KI. Collagens, modifying enzymes and their mutations in humans, flies and worms. Trends Genet (2004) 20:33-43. doi:10.1016/j.tig.2003.11.004
78. Egbert M, Ruetze M, Sattler M, Wenck H, Gallinat S, Lucius R, et al. The matricellular protein periostin contributes to proper collagen function and is downregulated during skin aging. J Dermatol Sci (2014) 73:40-8. doi:10.1016/j.jdermsci.2013.08.010
79. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 15:786-801. doi:10.1038/nrm3904
80. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res (2000) 60:1254-60.
81. Hellevik T, Pettersen I, Berg V, Bruun J, Bartnes K, Busund LT, et al. Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: potential impact on angiogenesis and tumor growth. Transl Oncol (2013) 6:66-74. doi:10.1593/tlo.12349
82. Lotti F, Jarrar AM, Pai RK, Hitomi M, Lathia J, Mace A, et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J Exp Med (2013) 210:2851-72. doi:10.1084/jem.20131195
83. Hsu HW, Wall NR, Hsueh CT, Kim S, Ferris RL, Chen CS, et al. Combination antiangiogenic therapy and radiation in head and neck cancers. Oral Oncol (2014) 50:19-26. doi:10.1016/j.oraloncology.2013.10.003
84. Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology (2013) 2:e25962. doi:10.4161/onci.25962
85. Shahabi V, Postow MA, Tuck D, Wolchok JD. Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. Am J Clin Oncol (2015) 38:90-7. doi:10.1097/COC.0b013e3182868ec8
86. Stylianopoulos T, Jain RK. Combining two strategies to improve perfusion and drug delivery in solid tumors. Proc Natl Acad Sci U S A (2013) 110:18632-7. doi:10.1073/pnas.1318415110
87. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med (1971) 285:1182-6. doi:10.1056/NEJM197111182852108
88. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307:58-62. doi:10.1126/science.1104819
89. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med (2001) 7:987-9. doi:10.1038/nm0901-987
90. Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 370:734-43. doi:10.1056/NEJMoa1309748
91. Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol (2014) 73:495-501. doi:10.1007/s00280-014-2384-1
92. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A (2015) 112:1547-52. doi:10.1073/pnas.1424024112
93. Brandes AA, Mason W, Pichler J, Nowak AK, Gil M, Saran F, et al. Can bevacizumab prolong survival for glioblastoma patients through multiple lines of therapy? Future Oncol (2014) 10:1137-45. doi:10.2217/fon.14.75
94. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to anti-angiogenic therapy with elevated blood perfusion. Cancer Res (2012) 72:402-7. doi:10.1158/0008-5472.CAN-11-2464
95. Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A (2013) 110:19059-64. doi:10.1073/pnas.1318022110
96. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A (1996) 93:14765-70. doi:10.1073/pnas.93.25.14765
97. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell (2004) 6:553-63. doi:10.1016/S1535-6108(04)00305-8
98. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res (2013) 73:7144-6. doi:10.1158/0008-5472.CAN-13-1989
99. Willett CG, Boucher Y, Di Tomaso E, Duda DG, Munn LL, Tong RT, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 10:145-7. doi:10.1038/nm988
100. Batchelor TT, Sorensen AG, Di Tomaso E, Zhang WT, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell (2007) 11:83-95. doi:10.1016/j.ccr.2006.11.021
101. Motzer RJ, Hutson TE, Tomczak P, Michaelson D, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 356:115-24. doi:10.1056/NEJMoa065044
102. Willett CG, Duda DG, Di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 27:3020-6. doi:10.1200/JCO.2008.21.1771
103. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, Mcintyre D, Honess D, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 324:1457-61. doi:10.1126/science.1171362
104. Lee JJ, Perera RM, Wang H, Wu DC, Liu XS, Han S, et al. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A (2014) 111:E3091-100. doi:10.1073/pnas.1411679111
105. Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 25:719-34. doi:10.1016/j.ccr.2014.04.005
106. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell (2014) 25:735-47. doi:10.1016/j.ccr.2014.04.021
107. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 108:2909-14. doi:10.1073/pnas.1018892108
108. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels. Nat Commun (2013) 4:2516. doi:10.1038/ncomms.3516
109. Liu J, Liao S, Diop-Frimpong B, Chen W, Goel S, Naxerova K, et al. TGF-beta blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci U S A (2012) 109:16618-23. doi:10.1073/pnas.1117610109
110. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2012) 62:112-20. doi:10.1136/gutjnl-2012-302529
111. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21:418-29. doi:10.1016/j.ccr.2012.01.007
112. Chauhan VP, Boucher Y, Ferrone CR, Roberge S, Martin JD, Stylianopoulos T, et al. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure. Cancer Cell (2014) 26:14-5. doi:10.1016/j.ccr.2014.06.003
113. Wilop S, Von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol (2009) 135:1429-35. doi:10.1007/s00432-009-0587-3
114. Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer (2010) 103:1644-8. doi:10.1038/sj.bjc.6605955
115. Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, et al. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer (2011) 47:1955-61. doi:10.1016/j.ejca.2011.04.019
116. Kohli AG, Kivimäe S, Tiffany MR, Szoka FC. Improving the distribution of Doxil® in the tumormatrix by depletion of tumor hyaluronan. J Control Release (2014) 191:105-14. doi:10.1016/j.jconrel.2014.05.019
117. Pirentis AP, Polydorou C, Papageorgis P, Voutouri C, Mpekris F, Stylianopoulos T. Remodeling of extracellular matrix due to solid stress accumulation during tumor growth. Connect Tissue Res (2015) 19:1-10. doi:10.3109/03008207.2015.1047929
118. Chen CY, Bertozzi C, Zou Z, Yuan L, Lee JS, Lu M, et al. Blood flow reprograms lymphatic vessels to blood vessels. J Clin Invest (2012) 122:2006-17. doi:10.1172/JCI57513
119. Vakoc BJ, Lanning RM, Tyrrell JA, Padera TP, Bartlett LA, Stylianopoulos T, et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat Med (2009) 15:1219-23. doi:10.1038/nm.1971
120. Li JL, Goh CC, Keeble JL, Qin JS, Roediger B, Jain R, et al. Intravital multiphoton imaging of immune responses in the mouse ear skin. Nat Protoc (2012) 7:221-34. doi:10.1038/nprot.2011.438
121. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation (2010) 17:206-25. doi:10.1111/j.1549-8719.2010.00029.x
122. Tanaka K, Toiyama Y, Okugawa Y, Okigami M, Inoue Y, Uchida K, et al. In vivo optical imaging of cancer metastasis using multiphoton microscopy: a short review. Am J Transl Res (2014) 6:179-87.
123. Lathia JD, Gallagher J, Myers JT, Li M, Vasanji A, Mclendon RE, et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 6(9):e24807. doi:10.1371/journal.pone.0024807
124. Kienast Y, Von Baumgarten L, Fuhrmann M, Klinkert WEF, Goldbrunner R, Herms J, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med (2010) 16:116-22. doi:10.1038/nm.2072
125. Hulit J, Kedrin D, Gligorijevic B, Entenberg D, Wyckoff J, Condeelis J, et al. The use of fluorescent proteins for intravital imaging of cancer cell invasion. Methods Mol Biol (2012) 872:15-30. doi:10.1007/978-1-61779-797-2_2
126. Ferrarini M, Mazzoleni G, Steimberg N, Belloni D, Ferrero E. Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs. Rijeka: InTech (2013). doi:10.5772/54312
127. Gehler S, Baldassarre M, Lad Y, Leight JL, Wozniak MA, Riching KM, et al. Filamin A-beta1 integrin complex tunes epithelial cell response to matrix tension. Mol Biol Cell (2009) 20:3224-38. doi:10.1091/mbc.E08-12-1186
128. Szot CS, Buchanan CF, Freeman JW, Rylander MN. 3D in vitro bioengineered tumors based on collagen I hydrogels. Biomaterials (2011) 32:7905-12. doi:10.1016/j.biomaterials.2011.07.001
129. Mason BN, Starchenko A, Williams RM, Bonassar LJ, Reinhart-King CA. Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behavior. Acta Biomater (2013) 9:4635-44. doi:10.1016/j.actbio.2012.08.007
130. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell (2009) 139:891-906. doi:10.1016/j.cell.2009.10.027
131. Brekhman V, Neufeld G. A novel asymmetric 3D in-vitro assay for the study of tumor cell invasion. BMC Cancer (2009) 9:415. doi:10.1186/1471-2407-9-415
132. David L, Dulong V, Le Cerf D, Chauzy C, Norris V, Delpech B, et al. Reticulated hyaluronan hydrogels: a model for examining cancer cell invasion in 3D. Matrix Biol (2004) 23:183-93. doi:10.1016/j.matbio.2004.05.005
133. Gurski LA, Jha AK, Zhang C, Jia X, Farach-Carson MC. Hyaluronic acid-based hydrogels as 3D matrices for in vitro evaluation of chemotherapeutic drugs using poorly adherent prostate cancer cells. Biomaterials (2009) 30:6076-85. doi:10.1016/j.biomaterials.2009.07.054
134. Rao SS, Dejesus J, Short AR, Otero JJ, Sarkar A, Winter JO. Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels. ACS Appl Mater Interfaces (2013) 5:9276-84. doi:10.1021/am402097j
135. Weigelt B, Ghajar CM, Bissell MJ. The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev (2014) 6(9-70):42-51. doi:10.1016/j.addr.2014.01.001
136. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol (1997) 15:778-83. doi:10.1038/nbt0897-778
137. Delarue M, Montel F, Vignjevic D, Prost J, Joanny JF, Cappello G. Compressive stress inhibits proliferation in tumor spheroids through a volume limitation. Biophys J (2014) 107:1821-8. doi:10.1016/j.bpj.2014.08.031
138. Keely PJ, Fong AM, Zutter MM, Santoro SA. Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci (1995) 108(Pt 2):595-607.
139. Miki Y, Ono K, Hata S, Suzuki T, Kumamoto H, Sasano H. The advantages of co-culture over mono cell culture in simulating in vivo environment. J Steroid Biochem Mol Biol (2012) 131:68-75. doi:10.1016/j.jsbmb.2011.12.004
140. Schreiber-Brynzak E, Klapproth E, Unger C, Lichtscheidl-Schultz I, Goschl S, Schweighofer S, et al. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest New Drugs (2015) 33:835-47. doi:10.1007/s10637-015-0260-4
141. Girard YK, Wang C, Ravi S, Howell MC, Mallela J, Alibrahim M, et al. A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development. PLoS One (2013) 8:e75345. doi:10.1371/journal.pone.0075345
142. Saha S, Duan X, Wu L, Lo PK, Chen H, Wang Q. Electrospun fibrous scaffolds promote breast cancer cell alignment and epithelial-mesenchymal transition. Langmuir (2012) 28:2028-34. doi:10.1021/la203846w
143. Nelson CM, Bissell MJ. Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation. Semin Cancer Biol (2005) 15:342-52. doi:10.1016/j.semcancer.2005.05.001
144. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, et al. Engineering tumors with 3D scaffolds. Nat Methods (2007) 4:855-60. doi:10.1038/nmeth1085
145. DelNero P, Lane M, Verbridge SS, Kwee B, Kermani P, Hempstead B, et al. 3D culture broadly regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. Biomaterials (2015) 55:110-8. doi:10.1016/j.biomaterials.2015.03.035
146. Gadegaard N. Atomic force microscopy in biology: technology and techniques. Biotech Histochem (2006) 81:87-97. doi:10.1080/10520290600783143
147. Stylianou A, Yova D. Surface nanoscale imaging of collagen thin films by atomic force microscopy. Mater Sci Eng C Mater Biol Appl (2013) 33:2947-57. doi:10.1016/j.msec.2013.03.029
148. Stylianou A, Kontomaris SV, Yova D. Assessing collagen nanoscale thin films heterogeneity by AFM multimode imaging and nanoindetation for nanobiomedical applications. Micro Nanosyst (2014) 6:95-102. doi:10.2174/187640290602141127114448
149. Stylianou A, Yova D, Alexandratou E. Investigation of the influence of UV irradiation on collagen thin films by AFM imaging. Mater Sci Eng C (2014) 45:455-68. doi:10.1016/j.msec.2014.09.006
150. Morris VJ, Kirby AR, Gunning AP. Atomic Force Microscopy for Biologists. London: Imperial College Press (2008).
151. Stylianou A, Yova D, Alexandratou E. Nanotopography of collagen thin films in correlation with fibroblast response. J Nanophotonics (2013) 7(1):073590. doi:10.1117/1.JNP.7.073590
152. Kontomaris SV, Yova D, Stylianou A, Balogiannis G. The effects of UV irradiation on collagen D-band revealed by atomic force microscopy. Scanning (2015) 37:101-11. doi:10.1002/sca.21185
153. O'Connor J, Gomez E. Biomechanics of TGFbeta-induced epithelial-mesenchymal transition: implications for fibrosis and cancer. Clin Transl Med (2014) 3:23. doi:10.1186/2001-1326-3-23
154. Schneider D, Baronsky T, Pietuch A, Rother J, Oelkers M, Fichtner D, et al. Tension monitoring during epithelial-to-mesenchymal transition links the switch of phenotype to expression of moesin and cadherins in NMuMG cells. PLoS One (2013) 8(12):e80068. doi:10.1371/journal.pone.0080068
155. Pittet P, Lee K, Kulik AJ, Meister JJ, Hinz B. Fibrogenic fibroblasts increase intercellular adhesion strength by reinforcing individual OB-cadherin bonds. J Cell Sci (2008) 121:877-86. doi:10.1242/jcs.024877
156. Thoelking G, Reiss B, Wegener J, Oberleithner H, Pavenstaedt H, Riethmuller C. Nanotopography follows force in TGF-β1 stimulated epithelium. Nanotechnology (2010) 21(26):265102. doi:10.1088/0957-4484/21/26/265102
157. Buckley ST, Medina C, Davies AM, Ehrhardt C. Cytoskeletal re-arrangement in TGF-β1-induced alveolar epithelial-mesenchymal transition studied by atomic force microscopy and high-content analysis. Nanomedicine (2012) 8:355-64. doi:10.1016/j.nano.2011.06.021
158. Chasiotis I, Fillmore HL, Gillies GT. Atomic force microscopy measurement of cytostructural elements involved in the nanodynamics of tumour cell invasion. Nanotechnology (2003) 14:557-61. doi:10.1088/0957-4484/14/5/314
159. Fillmore HL, Chasiotis I, Cho SW, Gillies GT. Atomic force microscopy observations of tumour cell invadopodia: novel cellular nanomorphologies on collagen substrates. Nanotechnology (2003) 14:73-6. doi:10.1088/0957-4484/14/1/317
160. Kusick S, Bertram H, Oberleithner H, Ludwig T. Nanoscale imaging and quantification of local proteolytic activity. J Cell Physiol (2005) 204:767-74. doi:10.1002/jcp.20328
161. Ludwig T. Local proteolytic activity in tumor cell invasion and metastasis. Bioessays (2005) 27:1181-91. doi:10.1002/bies.20306
162. Ludwig T, Kirmse R, Poole K. Challenges and approaches-probing tumor cell invasion by atomic force microscopy. In: Méndez-Vilas A, Díaz J, editors. Modern Research and Educational Topics in Microscopy. Badajoz: Formatex (2007). p. 11-22.
163. Park S, Lee YJ. AFM-based dual nano-mechanical phenotypes for cancer metastasis. J Biol Phys (2014) 40:413-9. doi:10.1007/s10867-014-9353-0
164. Laurent VM, Duperray A, Sundar Rajan V, Verdier C. Atomic force microscopy reveals a role for endothelial cell ICAM-1 expression in bladder cancer cell adherence. PLoS One (2014) 9(5):e98034. doi:10.1371/journal.pone.0098034
165. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 31:2205-18. doi:10.1200/JCO.2012.46.3653